Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1998-10-22
|
pubmed:abstractText |
In esophageal carcinoma, individual genetic alterations of cyclins, cyclin-dependent kinase inhibitors, and final effectors of the G1-to-S transition have been documented. Our aim was to design a comprehensive analysis of the role and clinical significance of some critical genes, namely cyclin D1, MTS1, and Rb. To this end, cyclin D1 gene amplification and protein accumulation, Rb gene allelic loss and protein expression, and MTS1 gene mutation and DNA methylation were investigated in a series of 74 esophageal carcinomas. Cyclin D1 amplification was documented in 17 of 55 (31 %) cases, being a feature of squamous cell type (14 of 17 amplified cases). Cyclin D1 accumulation significantly correlated with lymph node metastasis (p < 0.02), advanced tumor stage (p < 0.05), and a reduced overall survival rate (p < 0.03). Rb gene loss of heterozygosity occurred in 14 of 39 (36%) informative cases and was associated with an unfavorable survival rate (p < 0.01). MTS1 gene mutations were detected in 2 adenocarcinomas only; gene methylation was observed in 17 of 72 cases (24%) without any correlations with the variables investigated. A direct association between cyclin D1 and Rb gene accumulation (p < 0.0005) and an inverse one between RB loss of heterozygosity and MTS1 abnormalities (p < 0.05) emerged from this study. These results have important clinical implications because both cyclin D1 and Rb gene deregulation are significantly related to an unfavorable survival rate. In addition, cyclin D1 amplification is associated with esophageal carcinoma of squamous cell type, being totally absent in adenocarcinomas (p < 0.01). The combined evaluation of these genes also demonstrates that molecular abnormalities of genes belonging to the same pathway are mutually exclusive and unnecessary for the neoplastic transformation and tumor progression.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0023-6837
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
78
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1049-57
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9759649-Carcinoma,
pubmed-meshheading:9759649-Cell Cycle,
pubmed-meshheading:9759649-Cyclin D1,
pubmed-meshheading:9759649-Cyclin-Dependent Kinase Inhibitor p16,
pubmed-meshheading:9759649-Esophageal Neoplasms,
pubmed-meshheading:9759649-Gene Amplification,
pubmed-meshheading:9759649-Gene Expression,
pubmed-meshheading:9759649-Genes, Retinoblastoma,
pubmed-meshheading:9759649-Humans,
pubmed-meshheading:9759649-Loss of Heterozygosity,
pubmed-meshheading:9759649-Methylation,
pubmed-meshheading:9759649-Mutation,
pubmed-meshheading:9759649-Retinoblastoma Protein
|
pubmed:year |
1998
|
pubmed:articleTitle |
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma.
|
pubmed:affiliation |
Department of Pathology, Humanitas Clinical Institute, University, University of Milan School of Medicine, Rozzano, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|